Celltrion两款美国新生物类似药Omlyclo/Avtozma获大型医疗公司独家供应与优选处方地位，但未披露对手方及任何金额

Celltrion (068270.KS) is expanding its U.S. sales network by exclusively supplying Omlyclo, an allergy treatment, and Avtozma, an autoimmune disease treatment, to a large U.S. healthcare company.
Celltrion said on Oct. 26 that its U.S. unit signed exclusive supply agreements early this month for Omlyclo in prefilled syringe form and for all formulations of Avtozma, both intravenous and subcutaneous. That healthcare company operates multiple large hospitals, insurers and pharmacy benefit managers.
A PBM negotiates drug prices and reimbursement terms with pharmaceutical companies on behalf of insurers in the U.S. and manages lists of drugs covered by insurance. Being listed as a preferred drug on a formulary helps expand prescriptions, as it secures favorable terms on patient out-of-pocket costs and prescription restrictions.
Under the agreements, the two products will be listed as preferred drugs on the insurer's formulary and supplied to its affiliated medical institutions. They were selected as exclusive supply products over the originator drugs, with supply and insurance reimbursement beginning this month. Celltrion secured the additional supply channel on the strength of a partnership built through earlier supplies of its bone disease treatments Stoboclo and Osenvelt.
Omlyclo has also entered the sales network of a large U.S. retailer. Sales have begun at pharmacies inside the retailer's stores, and the drug has been listed as the sole preferred drug in the prescription segment — excluding some vial formulations — on an insurance channel used by about 350,000 employee health plan members.
It was also registered in a drug discount program covering about 74 million members. People without insurance and their dependents can buy Omlyclo at discounted prices at the retailer's pharmacies and partner pharmacies.
Celltrion is also negotiating with several large PBMs on formulary listings for its new products. The company expects to sign additional contracts within the fourth quarter. "If the negotiations succeed, insurance reimbursement channels in the U.S. will expand, which should support prescription growth and higher sales for the new products," a Celltrion official said.
"Omlyclo and Avtozma have entered the supply channels of a large healthcare company and a large retailer from the early stage of their U.S. launch, demonstrating their product competitiveness and our direct sales capabilities," said Kim Bon-joong, CEO of Celltrion's U.S. unit. "We will translate the confirmed supply agreements into actual prescriptions and sales growth, and swiftly complete the PBM listings now under negotiation."